Skip to content
Circumvent logo

Circumvent

Circumvent is a YC Summer 2018 (S18) company. Team of 6.

  • Neurotechnology
  • Biotech
  • Genomics

About Circumvent

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Circumvent develops precision medicines for neurodegenerative diseases, starting with Batten Disease, a rare fatal disorder. Research into Batten Disease has surfaced mechanistic insights into synaptic function, protein localization, lysosomal activity, and the palmitoylome, a set of lipid-modified proteins central to brain-cell health. Circumvent applies these findings across both rare and common neurodegenerative conditions, replacing the field's reliance on low-fidelity disease models with genetically defined, high-predictivity biology.

From the Y Combinator listing

How Circumvent describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Utilizing monogenic disorders to inform and solve highly complex…

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Team size
6
Status
Active
Stage
Early

Founders (1)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works